Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

被引:547
作者
van Meerbeeck, Jan P.
Kramer, Gijs W. P. M.
Van Schil, Paul E. Y.
Legrand, Catherine
Smit, Egbert F.
Schramel, Franz
Tjan-Heijnen, Vivianne C.
Biesma, Bonne
Debruyne, Channa
van Zandwijk, Nico
Splinter, Ted A. W.
Giaccone, Giuseppe
机构
[1] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium
[2] Arnhem Radiotherapeut Inst, Dept Radiat Therapy, Arnhem, Netherlands
[3] Univ Hosp Antwerp, Dept Resp Med, Antwerp, Belgium
[4] Univ Hosp Antwerp, Dept Thorac Surg, Antwerp, Belgium
[5] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[6] Vrije Univ Amsterdam, Dept Pulmonol, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[8] St Antonius Hosp, Dept Pulmonol, Nieuwegein, Netherlands
[9] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[10] Jeroen Bosch Ziekenhuis, Dept Pulmonol, Shertogenbosch, Netherlands
[11] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[12] Erasmus MC, Dept Pulmonol, Rotterdam, Netherlands
[13] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 06期
关键词
D O I
10.1093/jnci/djk093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. Methods Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. Results Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [Cl] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% Cl = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. Conclusion In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 50 条
[21]   A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) [J].
van Meerbeeck, J ;
Van Schil, P ;
Kramer, G ;
Legrand, C ;
O'Brien, M ;
Manegold, C ;
Passioukov, A ;
Giaccone, G ;
van Zandwijk, N ;
Splinter, T .
LUNG CANCER, 2005, 49 :S4-S4
[22]   Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial [J].
Senan, S. ;
Ozguroglu, M. ;
Daniel, D. ;
Villegas, A. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Faivre-Finn, C. ;
Paz-Ares, L. ;
Wu, Y. L. ;
Mann, H. ;
Dennis, P. A. ;
Antonia, S. J. .
ESMO OPEN, 2022, 7 (02)
[23]   A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) [J].
van Meerbeeck, J. ;
Kramer, G. ;
Van Schil, P. ;
Legrand, C. ;
Passioukov, A. ;
O'Brien, M. ;
van Zandwijk, N. ;
Giaccone, G. ;
Manegold, C. ;
Splinter, T. .
EJC SUPPLEMENTS, 2005, 3 (02) :323-323
[24]   Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer [J].
Selek, Ugur ;
Chang, Joe Y. .
JOURNAL OF THORACIC DISEASE, 2016, 8 (07) :1394-1397
[25]   Postoperative radiotherapy in non-small cell lung cancer stage IIIA-N2: Focus and perspectives [J].
Wang, Pascal ;
Duchemann, Boris ;
Chouahnia, Kader ;
Matton, Lise ;
Benabadji, Ambre ;
Zelek, Laurent ;
Popotte, Hosni ;
Paix, Adrien .
BULLETIN DU CANCER, 2023, 110 (01) :101-112
[26]   Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer [J].
Mathisen, DJ ;
Wain, JC ;
Wright, C ;
Choi, N ;
Carey, R ;
Hilgenberg, A ;
Grossbard, M ;
Lynch, T ;
Grillo, H .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (01) :123-131
[27]   Postoperative Radiotherapy in Completely Resected Stage IIIA-N2 Non-Small Cell Lung Cancer [J].
Ahn, S. ;
Na, K. ;
Kim, Y. ;
Song, S. ;
Oh, I. ;
Park, C. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S2180-S2181
[28]   Risk Associated with Bilobectomy after Neoadjuvant Concurrent Chemoradiotherapy for Stage IIIA-N2 Non-small-cell Lung Cancer [J].
Jong Ho Cho ;
Jhingook Kim ;
Kwhanmien Kim ;
Young Mog Shim ;
Hong Kwan Kim ;
Yong Soo Choi .
World Journal of Surgery, 2012, 36 :1199-1205
[30]   Preresectional chemotherapy in stage IIIA non-small-cell lung cancer:: a 7-year assessment of a randomized controlled trial [J].
Rosell, R ;
Gómez-Codina, J ;
Camps, C ;
Sánchez, JJ ;
Maestre, J ;
Padilla, J ;
Cantó, A ;
Abad, A ;
Roig, J .
LUNG CANCER, 1999, 26 (01) :7-14